Author

Ann M. Lowe

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

2009 · Jonathan W. Friedberg, Jeff Sharman, et al. · Blood · 747

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

2017 · Kevin D. Courtney, Jeffrey R. Infante, et al. · Journal of Clinical Oncology · 391

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study

2006 · Paul Harmatz, Roberto Giugliani, et al. · The Journal of Pediatrics · 365

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

2009 · Srdan Verstovsek, Olatoyosi Odenike, et al. · Blood · 77

A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.

2012 · Samantha Mary Jaglowski, Jeffrey Alan Jones, et al. · Journal of Clinical Oncology · 65

Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.

2010 · R. Tibes, G. S. Falchook, et al. · Journal of Clinical Oncology · 46

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

2011 · Ramesh K. Ramanathan, Joe J. Stephenson, et al. · Investigational New Drugs · 42

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

2008 · Jonathan W. Friedberg, Jeff Sharman, et al. · Blood · 29

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

2006 · David S. Siegel, A. Krishnan, et al. · Blood · 20

Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study

2018 · David J. Kuter, Richy Agajanian, et al. · Blood · 7

Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).

2006 · Lubomir Sokol, Larry Cripe, et al. · Blood · 3

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

2019 · Nichola Cooper, Isabel Gorham, et al. · Blood

Pf427 Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Open‐label Extension Period of the Soar Phase 2 Study

2019 · D. Kuter, A. Richy, et al. · HemaSphere

Works count: 14

Citation count: 1,792

H-index: 9

I10-index: 9